Evidence map›Paper›PMID 35015199›Full record

ReviewMetabolic brain disease2022

Promising protein biomarkers in the early diagnosis of Alzheimer's disease.

Lalit Sharma, Aditi Sharma, Deepak Kumar, Manish Kumar Asthana, H Lalhlenmawia, Ashwani Kumar, Sanjib Bhattacharyya, Deepak Kumar

Abstract readReview
PubMed Publisher
In one paragraph

Review in Metabolic brain disease, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed
2.1field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed, 19 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. Review
  5. Article
  6. Review
  7. Article
  8. Review
  9. Biomarkers of Activity-Dependent Plasticity and Persistent Enhancement of Synaptic Transmission in Alzheimer Disease: A Review of the Current Status.Medical science monitor : international medical journal of experimental and clinical research · 2023
    Review
  10. Article
  11. Review
  12. Review
  13. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 4 institutions in 2 countries.

Lalit SharmaDepartment of Pharmacology, School of Pharmaceutical Sciences, Shoolini University, Solan, 173229, India.
Aditi SharmaDepartment of Pharmacology, School of Pharmaceutical Sciences, Shoolini University, Solan, 173229, India.
Deepak KumarDepartment of Pharmacology, School of Pharmaceutical Sciences, Shoolini University, Solan, 173229, India.
Manish Kumar AsthanaDepartment of Humanities & Social Sciences, Indian Institute of Technology Roorkee, Roorkee, 247667, India.
H LalhlenmawiaDepartment of Pharmacy, Regional Institute of Paramedical and Nursing Sciences, Zemabawk, Aizawl, 796017, India.
Ashwani KumarCouncil of Scientific and Industrial Research, Institute of Himalayan Bioresource Technology (CSIR-IHBT), Palampur, 176061, India.
Sanjib BhattacharyyaDepartment of Pharmaceutical Sciences and Chinese Traditional Medicine, Southwest University, Chongqing, 400715, People's Republic of China. bhattacharyya.sanjib2k12@gmail.com.
Deepak KumarDepartment of Pharmaceutical Chemistry, School of Pharmaceutical Sciences, Shoolini University, Solan, 173 229, India. guptadeepak002@gmail.com.ORCID 0000-0003-2241-0054
Shoolini University · INIndian Institute of Technology Roorkee · INInstitute of Himalayan Bioresource Technology · INSouthwest University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Alzheimer's disease (AD) is an insidious, multifactorial disease that involves the devastation of neurons leading to cognitive impairments. Alzheimer's have compounded pathologies of diverse nature, including proteins as one important factor along with mutated genes and enzymes. Although various review articles have proposed biomarkers, still, the statistical importance of proteins is missing. Proteins associated with AD include amyloid precursor protein, glial fibrillary acidic protein, calmodulin-like skin protein, hepatocyte growth factor, matrix Metalloproteinase-2. These proteins play a crucial role in the AD hypothesis which includes the tau hypothesis, amyloid-beta (Aβ) hypothesis, cholinergic neuron damage, etc. The present review highlights the role of major proteins and their physiological functions in the early diagnosis of AD. Altered protein expression results in cognitive impairment, synaptic dysfunction, neuronal degradation, and memory loss. On the medicinal ground, efforts of making anti-amyloid, anti-tau, anti-inflammatory treatments are on the peak, having these proteins as putative targets. Few proteins, e.g., Amyloid precursor protein results in the formation of non-soluble sticky Aβ

Indexed as

Alzheimer DiseaseAmyloid beta-PeptidesAmyloid beta-Protein PrecursorBiomarkersCalcium-Binding ProteinsEarly DiagnosisGlial Fibrillary Acidic ProteinHepatocyte Growth FactorHumansMatrix Metalloproteinase 2tau ProteinsAmyloid beta-PeptidesAmyloid beta-Protein PrecursorBiomarkersCalcium-Binding ProteinsCALML5 protein, humanGlial Fibrillary Acidic ProteinHepatocyte Growth FactorHGF protein, humanMatrix Metalloproteinase 2MMP2 protein, humantau ProteinsAlzheimer’s diseaseBiomarkersDiagnosisNeurodegenerationProteins

Identifiers

PMID35015199
OpenAlexW4205597134

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.